#KYMR hashtag - Bluesky

1 week ago

Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting Kymera Therapeutics (NASDAQ: KYMR) reported positive Phase 1b BroADen results for oral STAT6 degrader KT-621, presented at AAD 2026. In 22 moderate-to-severe atopic dermatitis patients, 28-day dosing produced median STAT6 degradation up to 98% in blood and meaningful reductions in clinical and biomarker endpoints.Parallel Phase 2b trials in atopic dermatitis (BROADEN2) and asthma (BREADTH) are ongoing, with data expected by mid-2027 and late-2027, respectively.

#KYMR Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

3 weeks ago

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting Kymera Therapeutics (NASDAQ: KYMR) announced that data from its KT-621 BroADen Phase 1b trial in moderate-to-severe atopic dermatitis will be presented as a late-breaking oral presentation at the American Academy of Dermatology (AAD) 2026 Annual Meeting.The oral session is scheduled for March 28, 2026 at 9:24 AM MT in Bellco Theatre, Denver. Kymera will also host a booth (#3551) in the exhibit hall. A copy of the presentation will be posted in Kymera's Resource Library after the session.

#KYMR Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

1 month ago

Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update Kymera Therapeutics (NASDAQ: KYMR) reported Q4 and full-year 2025 results, advanced multiple clinical programs, and strengthened its balance sheet. Key highlights include $1.6 billion in cash (runway into 2029), positive KT-621 Phase 1b atopic dermatitis data, FDA Fast Track for KT-621, initiation of KT-579 Phase 1 dosing, and ongoing KT-621 Phase 2b studies with data expected mid-2027 (AD) and late-2027 (asthma).

#KYMR Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

2 months ago

Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs Kymera Therapeutics (NASDAQ: KYMR) outlined 2026 objectives to advance its oral immunology portfolio, highlighting clinical and preclinical milestones for STAT6 degrader KT-621 and IRF5 degrader KT-579.Key points: KT-621 BROADEN2 Phase 2b in atopic dermatitis Fast Track in AD KT-579 Phase 1 healthy volunteer trial to start in 1Q26 with data in 2H26. Company reports $1.6 billion cash runway into 2029 and plans to advance at least one new development candidate toward IND in 2026.

#KYMR Kymera Therapeutics Outlines Key 2026 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis Kymera Therapeutics (NASDAQ: KYMR) announced that the U.S. FDA granted Fast Track designation to KT-621, a first-in-class oral STAT6 degrader for moderate to severe atopic dermatitis (AD), on December 11, 2025.Fast Track follows positive BroADen Phase 1b AD results showing STAT6 degradation, biomarker modulation, clinical activity and supportive safety. The KT-621 BROADEN2 Phase 2b AD trial is ongoing with data expected by mid-2027, and the BREADTH Phase 2b asthma trial is planned to start in 1Q 2026. The company intends these studies to enable dose selection for parallel Phase 3 registration studies across Type 2 indications.

#KYMR Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Atopic Dermatitis

www.stocktitan.net/news/KYMR/kymera-therape...

1 0 0 0

StockTitan

@stocktitan.net

3 months ago

Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering Kymera Therapeutics (NASDAQ: KYMR) priced an upsized underwritten public offering of 7,000,000 shares at $86.00 per share, raising approximately $602.0 million in gross proceeds; underwriters have a 30‑day option to buy up to an additional 1,050,000 shares at the offering price, less discounts and commissions.The offering is expected to close on December 11, 2025, subject to customary conditions. Net proceeds are intended to fund advancement of preclinical and clinical degrader programs and for working capital and general corporate purposes. The offering is made from an effective Form S-3 shelf registration filed October 31, 2024.

#KYMR Kymera Therapeutics Announces Pricing of Upsized $602 Million Public Offering

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

3 months ago

Kymera Therapeutics Announces Proposed Public Offering Kymera Therapeutics (NASDAQ: KYMR) commenced a proposed underwritten public offering of $500.0 million of common stock, with a 30-day underwriter option to purchase up to an additional $75.0 million.The offering is subject to market and other conditions and may not be completed as proposed. Kymera intends to use net proceeds to advance its preclinical and clinical degrader programs and for working capital and general corporate purposes. The securities are offered under an effective Form S-3 shelf registration (No. 333-282912).

#KYMR Kymera Therapeutics Announces Proposed Public Offering

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

4 months ago

Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Kymera Therapeutics (NASDAQ: KYMR) announced dosing has begun in the BROADEN2 Phase 2b trial of KT-621, an oral STAT6 degrader for moderate to severe atopic dermatitis (AD). The randomized, double-blind, placebo-controlled, dose-ranging study will enroll ~200 patients treated over 16 weeks with three dose arms and a primary endpoint of percent change in EASI score at Week 16.The company expects BROADEN2 data by mid-2027, completed dosing in the Phase 1b BroADen trial with data due December 2025, and plans to initiate the BREADTH Phase 2b asthma trial in 1Q 2026. Patients may enter a 52-week open-label extension after the trial.

#KYMR Kymera Therapeutics Announces First Patient Dosed in BROADEN2 Phase 2b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update Kymera Therapeutics (NASDAQ: KYMR) reported third-quarter 2025 results and pipeline progress. Key financials include cash of $978.7 million as of September 30, 2025, and an expected cash runway into the second half of 2028. The company posted a net loss of $82.2 million with R&D expense of $74.1 million in Q3.Clinical highlights: KT-621 completed enrollment and dosing in the BroADen Phase 1b atopic dermatitis study with data expected in December 2025, initiated the BROADEN2 Phase 2b in AD, and is on track to start the BREADTH Phase 2b asthma trial in 1Q 2026. KT-579 completed IND-enabling studies with Phase 1 expected in early 2026.

#KYMR Kymera Therapeutics Announces Third Quarter 2025 Financial Results and Provides a Business Update

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

5 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting KT-579, a potent, selective, oral degrader of IRF5, demonstrated broad activity across multiple preclinical models of lupus and rheumatoid arthritis (RA), with activity comparable or superior to approved and clinically active therapies KT-579 Phase 1 testing expected to begin in early 2026

#KYMR Kymera Therapeutics Presents New Preclinical Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at the American College of Rheumatology Annual Meeting

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

7 months ago

Kymera Revenue Drops 55 Percent in Q2 | The Motley Fool

#KYMR #971ad89b-93be-44da-a454-01861b2d6679 #data-news

Origin | Interest | Match

0 0 0 0

StockTitan

@stocktitan.net

7 months ago

Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update Kymera Therapeutics (NASDAQ: KYMR) reported significant Q2 2025 financial results and pipeline progress. The company announced positive Phase 1 data for KT-621, their oral STAT6 degrader, demonstrating complete STAT6 degradation and favorable safety profile. Kymera secured a strategic partnership with Gilead worth up to $750 million for CDK2 degrader development.Financial highlights include a strong cash position of $1 billion as of July 31, 2025, extending runway into H2 2028. Q2 2025 showed collaboration revenues of $11.5 million and a net loss of $76.6 million. The company completed a $288 million equity offering in June 2025.Pipeline developments include advancing KT-621 to Phase 2b trials in atopic dermatitis and asthma starting Q4 2025 and Q1 2026, respectively. KT-579, their IRF5 degrader, is progressing toward Phase 1 trials in early 2026.

#KYMR Kymera Therapeutics Announces Second Quarter 2025 Financial Results and Provides a Business Update

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Kymera Therapeutics Announces Pricing of $250 Million Public Offering Kymera Therapeutics (NASDAQ: KYMR), a clinical-stage biopharmaceutical company, has announced the pricing of a $250.8 million public offering of common stock and pre-funded warrants. The company is offering 5,044,500 shares at $44.00 per share and 655,500 pre-funded warrants at $43.9999 each.The offering includes a 30-day option for underwriters to purchase up to 855,000 additional shares. The proceeds will support Kymera's pipeline of preclinical and clinical degrader programs. The offering is expected to close on June 30, 2025, with Morgan Stanley, J.P. Morgan, Jefferies, TD Cowen, and Leerink Partners acting as joint book-running managers.

#KYMR Kymera Therapeutics Announces Pricing of $250 Million Public Offering

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Kymera Therapeutics Raises $250M in Public Offering to Advance Novel Degrader Medicines Pipeline Clinical-stage biotech seeks $250M plus $37.5M option to accelerate novel degrader medicines development. Morgan Stanley, JPMorgan lead offering. See growth strategy.

#KYMR Kymera Therapeutics Announces Proposed Public Offering

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update Kymera Therapeutics (NASDAQ: KYMR) announced that Sanofi will advance KT-485, their next-generation oral IRAK4 degrader, into clinical testing while discontinuing development of KT-474. KT-485 demonstrated enhanced selectivity, potency, and favorable safety in preclinical testing.Under their collaboration agreement, Kymera received a $20 million milestone payment in Q2 2025 and remains eligible for up to $975 million in potential milestones, plus double-digit royalties. Kymera maintains the option for a 50/50 development and profit share of KT-485 in the U.S.

#KYMR Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

9 months ago

Gilead Bets $750M on Revolutionary Oral Cancer Drug: New Breast Cancer Treatment Breakthrough? Gilead partners with Kymera on novel oral CDK2 degraders for breast cancer treatment. $750M deal includes breakthrough molecular technology. See development timeline.

#GILD #KYMR Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders

www.stocktitan.net/news/GILD/gilead-science...

0 0 0 0

Market Wire News

@marketwirenews.com

10 months ago

BREAKING NEWS: ( NASDAQ: #KYMR ) Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader Kymera Therapeutics announced positive Phase 1 results for KT-621, their first-in-class oral STAT6 degrader medicine. The trial demonstrated >90% STAT6 degradation in blood at doses above 1.5mg and complete degradation in both blood and skin at MAD doses ≥50mg. The drug showed impressive efficacy with TARC reduction up to 37% and Eotaxin-3 reduction up to 63%, comparable or superior to dupilumab. KT-621 exhibited excellent safety with no serious adverse events and a profile undifferentiated from placebo. The Phase 1 study included 118 healthy volunteers across single and multiple ascending dose cohorts. The company plans to advance KT-621 through their ongoing BroADen Phase 1b trial in atopic dermatitis patients, with data expected in Q4 2025, followed by Phase 2b trials in AD and asthma starting in Q4 2025 and Q1 2026 respectively.

#KYMR Kymera Therapeutics Announces Positive First-in-Human Results from Phase 1 Healthy Volunteer Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

First-in-Human Data: Kymera's Novel Protein Degrader KT-621 Phase 1 Results Coming June 2 Key safety and tolerability data from Kymera's innovative protein degrader KT-621 Phase 1 trial to be revealed. Join live presentation for complete findings.

#KYMR Kymera Therapeutics to Announce KT-621 Phase 1 Healthy Volunteer Trial Results on June 2, 2025

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference Kymera Therapeutics (NASDAQ: KYMR) presented new preclinical data for KT-621, their first-in-class oral STAT6 degrader, at the American Thoracic Society International Conference. The data showed that KT-621 demonstrated comparable or superior activity to dupilumab in a chronic asthma model, both preventing and reversing disease progression. The company has completed Phase 1 healthy volunteer SAD/MAD trials with data expected in June 2025. Their BroADen Phase 1b trial in atopic dermatitis is ongoing with results expected in Q4 2025. Kymera plans to initiate two parallel Phase 2b trials in atopic dermatitis and asthma in Q4 2025 and Q1 2026, respectively. The preclinical results suggest KT-621 could offer dupilumab-like efficacy with the convenience of a daily oral medication.

#KYMR Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

10 months ago

Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update Kymera Therapeutics reported Q1 2025 financial results and pipeline updates. Key highlights include: completion of KT-621 Phase 1 trial with data expected in June 2025, and first patient dosed in BroADen Phase 1b trial for atopic dermatitis. The company announced KT-579, a new oral IRF5 degrader program for autoimmune diseases, expected to enter clinical trials in early 2026. Kymera received a $20 million milestone payment from Sanofi for their IRAK4 collaboration. The company made a strategic decision to discontinue KT-295 (TYK2) development to focus resources on STAT6 program. Financial position remains strong with $775 million in cash, extending runway into first half of 2028. Q1 2025 results showed collaboration revenues of $22.1 million and a net loss of $65.6 million.

#KYMR Kymera Therapeutics Announces First Quarter 2025 Financial Results and Provides a Business Update

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

Nasdaq

@nasdaq.activitypub.awakari.com.ap.brid.gy

11 months ago

Original post on fool.com

www.fool.com/investing/2025/04/25/why...

#KYMR […]

[Original post on fool.com]

0 0 0 0

StockTitan

@stocktitan.net

11 months ago

Breakthrough Oral Treatment for Eczema: First Patient Receives New STAT6 Degrader Drug in Clinical Trial First-in-class oral STAT6 degrader enters patient trials for atopic dermatitis. Novel approach could revolutionize treatment. See trial endpoints.

#KYMR Kymera Therapeutics Announces First Patient Dosed in BROADEN Phase 1b Atopic Dermatitis Clinical Trial of KT-621, a First-in-Class Oral STAT6 Degrader

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update Kymera Therapeutics (NASDAQ: KYMR) reported its Q4 and full year 2024 financial results, highlighting significant progress in its immunology pipeline. The company maintains a strong financial position with $851 million in cash as of December 31, 2024, providing runway into mid-2027.Key pipeline updates include: KT-621 (STAT6) Phase 1 trial data expected June 2025, with Phase 1b trial in atopic dermatitis starting Q2 2025; KT-295 (TYK2) Phase 1 trial initiating Q2 2025; and ongoing KT-474/SAR444656 (IRAK4) Phase 2b trials in partnership with Sanofi.Financial results show collaboration revenues of $7.4 million for Q4 2024 and $47.1 million for full-year 2024. Net loss was $70.8 million for Q4 and $223.9 million for the full year. R&D expenses increased to $240.2 million for 2024, reflecting investment in pipeline development.

#KYMR Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

Kymera Unveils Ambitious 2025 Immunology Pipeline Plans with $850M Cash Runway Kymera advances oral immunology programs with multiple clinical milestones for KT-621, KT-295, and KT-474. Strong $850M cash position supports development through mid-2027.

#KYMR Kymera Therapeutics Outlines Key 2025 Objectives and Strategy to Advance Industry Leading Portfolio of Oral Immunology Programs

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

Market Wire News

@marketwirenews.com

1 year ago

NEWS: ( NASDAQ: #KYMR ) KYMR Price Target Alert: $55.00. Issued by BMO Capital

#StockMarket #News

0 0 0 0

StockTitan

@stocktitan.net

1 year ago

#KYMR Kymera Therapeutics to Participate in Upcoming December Investor Conferences

www.stocktitan.net/news/KYMR/kymera-therape...

0 0 0 0

Market Wire News